Baird Rates Definium Therapeutics (DFTX) buy, $57 Price Target
Baird reiterates its buy rating for Definium Therapeutics, setting a price target of $57, a 35.30% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Baird rated Definium Therapeutics, Inc. ($DFTX) "buy" with a $57 price target on June 23, 2026.
Since the rating, $DFTX is up 30.0% after 1 week, up 18.7% after 1 month and down 11.3% to date (from the $36.18 close on Jun 23, 2026).
DFTX
Definium Therapeutics, Inc.
Key Points
- On June 23, 2026, Baird reiterated its buy rating on Definium Therapeutics, Inc. (DFTX) with a price target of $57.
- Baird's $57 price target implies 35.30% upside from Definium Therapeutics, Inc.'s ($DFTX) current $42.13 share price.
- The stock is currently trading at $42.13, which is significantly above its 52-week low of $9.35 but below its high of $49.70.
- Definium has a market cap of approximately $5.28 billion and is focused on developing treatments for brain health disorders.
Get $DFTX trade alerts by text
We text you when insiders, Congress or big funds trade $DFTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures
Baird Reiterates Buy Rating for Definium Therapeutics
On June 23, 2026, Baird reiterated its buy rating for Definium Therapeutics, Inc. (DFTX) on the NasdaqGS, maintaining a price target of $57. The stock was trading at $42.13 at the time of the announcement, reflecting a positive outlook from Wall Street as it compares to its previous close of $38.81.
Baird vs. the S&P 500
Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.
Context of the Rating
Baird's decision to reiterate its buy rating comes as the stock has shown resilience, trading well above its 52-week low of $9.35. This rating suggests that Baird sees significant upside potential in Definium's future performance. The company is currently developing novel product candidates to treat brain health disorders, with its lead product DT120 in phase 3 trials for generalized anxiety disorder and major depressive disorder.
Analysts Set New Price Targets
Other analysts are also optimistic about Definium. On October 9, 2026, JP Morgan initiated coverage with an Overweight rating and a price target of $84. Canaccord Genuity maintained a Buy rating with a target of $78 on September 15, 2026, while Baird had previously set a target of $79 on the same day. HC Wainwright & Co. and Needham both reiterated their Buy ratings, with targets of $70 and $66, respectively, earlier in September. The average price target among analysts is about $71.65, indicating strong confidence in the company's growth potential.
How Definium Therapeutics, Inc. Stock Has Traded
Definium's stock is currently trading at $42.13, which is near its 50-day moving average of $42.28. This price reflects a notable rise from its 52-week low, but it still hasn't reached its 52-week high of $49.70. Investors may be encouraged by the stock's performance as it approaches its next earnings date on November 5, 2026.
$DFTX price target
Definium Therapeutics, Inc. daily closes and this analyst's $57 target. Not advice.
What Definium Therapeutics, Inc. Does
Definium Therapeutics, Inc., based in New York, is a clinical biopharmaceutical company focused on developing treatments for brain health disorders. Its innovative approach in this sector, particularly with products like DT120 and DT402, positions it well for future growth as it navigates clinical trials.
What’s Next for Definium
Looking ahead, investors will be watching for the upcoming earnings report on November 5, 2026, which will provide further insights into the company's financial health and progress. As a reminder, the ratings and targets provided by analysts are based on their assessments at the time and may not reflect future changes in the market or the company's position.
Related Filing Alerts
Source: Baird's rating change on $DFTX (Jun 23, 2026). Written by software, not financial advice. How we make alerts